drugset / Trial / NCT00509587

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

NCT00509587 ↗

Phase 2 Completed 21 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well giving pazopanib works in treating patients with recurrent or metastatic invasive breast cancer. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start
2007-06
Primary completion
2009-07
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule — Oral

Indications